Palido-OD 3 ER

Paliperidone is a second-generation atypical antipsychotic medication primarily indicated for the treatment of schizophrenia in adults and as monotherapy or adjunctive therapy with mood stabilizers or antidepressants for schizoaffective disorder in adults.[1][2] Its mechanism of action, while not fully elucidated, involves antagonism at central dopamine D2 and serotonin 5-HT2A receptors, similar to its parent compound risperidone, of which paliperidone is the major active metabolite.[3][4] First approved by the U.S. Food and Drug Administration in 2006 under the brand name Invega for oral extended-release tablets, paliperidone has since been formulated in long-acting injectable esters such as paliperidone palmitate (Invega Sustenna, Invega Trinza, and Invega Hafyera) to enhance treatment adherence in patients prone to non-compliance.[5][6]